Here’s an interesting device that has slipped through our cracks about two weeks ago. The easypod™ growth hormone (GH) delivery device has now been approved by the FDA, according to Merck Serono S.A., a division of the Swiss company Merck KGaA.
The electronic device is designed to simplify and ease the injection of somatropin of rDNA origin:
In developing easypod™, patients, caregivers and healthcare professionals were surveyed for input on how to improve upon delivery systems for growth hormone therapy. The device was designed to help patients administer a subcutaneous daily injection, reliably and in just three simple key steps. A key feature of easypod™is preset dosing, which means that patients no longer have to set their dose every day. It also tracks the number of doses administered, allowing physicians to monitor patient adherence to therapy.
easypod™ is intended for use with Saizen® click.easy cartridges after training from a healthcare provider. Although infrequent, injection site reactions can occur. easypod™ and Saizen® click.easy are available by prescription only.